« Back
Home /
Dehydrocorydaline

Dehydrocorydaline

Item no.	HY-N0674-1mg
Manufacturer	MedChem Express
CASRN	30045-16-0
Amount	1 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.77
Formula	C22H24NO4+
Citations	Bioengineered. 2022 May;13(5):12847-12862.<br>Exp Eye Res. 2022 Dec 25;109365.<br>Front Pharmacol. 31 May 2021.<br>J Inflamm Res. 2021 Sep 16;14:4669-4686.<br>Phytomedicine. 8 September 2021, 153740.<br>Tissue Cell. 2023 Sep 11, 102218.<br>Aging (Albany NY). 2021 Oct 7;13(19):23133-23148.<br>Aging. 2021 May 11;13(9):12780-12799.<br>Biochem Biophys Res Commun. 2018 May 23;499(4):743-750. <br>Biochem Biophys Res Commun. 2018 Sep 5;503(2):467-473. <br>BMC Musculoskelet Disord. 2022 May 30;23(1):514.<br>Bone Joint Res. 2023 Nov 1;12(11):677-690.<br>Comput Math Methods Med. 2021 Aug 2;2021:3337514.<br>Eur J Pharmacol. 2021 Mar 31;174069.<br>Infect Genet Evol. 2021 Nov 23;105158.<br>J Agric Food Chem. 2023 Oct 12.<br>J Cell Physiol. 2019 Dec;234(12):22463-22476.<br>J Clin Neurosci. 2020 Aug;78:365-370.<br>J Mol Histol. 2021 Feb 8.<br>J Nutr. 2020 Jul 1;150(7):1731-1737.<br>Int J Biol Macromol. 2024 Mar 15:130939.<br>Research Square Preprint. 2020 Dec.<br>[1]Xu Z, et al. Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells. Am J Chin Med. 2012;40(1):177-85.<br>[2]Yin ZY, et al. Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines. Sci Rep. 2016 Jun 7;6:27129.<br>[3]Yoo M, et al. Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation. Mol Med Rep. 2016 Oct;14(4):3029-36.<br>[4]Nonaka M, et al. Screening of a library of traditional Chinese medicines to identify anti-malarial compounds and extracts. Malar J. 2018 Jun 25;17(1):244.
Smiles	CC1=C(C=CC(OC)=C2OC)C2=C[N+]3=C1C4=CC(OC)=C(OC)C=C4CC3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	13-Methylpalmatine
Available
Product Description	Dehydrocorydaline (13-Methylpalmatine) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP[1]. Dehydrocorydaline elevates p38 MAPK activation. Anti-inflammatory and anti-cancer activities[2]. Dehydrocorydaline shows strong anti-malarial effects (IC50=38 nM), and low cytotoxicity (cell viability > 90%) using P. falciparum 3D7 strain[3].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Neuroscience-Neurodegeneration
MolecularWeight	366.43
Clinical_Information	No Development Reported
Manufacturers Research_Area	Cancer; Infection
Solubility	DMSO : 25 mg/mL (ultrasonic)
Manufacturers Target	Autophagy; Bcl-2 Family; Caspase; p38 MAPK; Parasite; PARP
Isoform	Bax; Bcl-2; Caspase 7; Caspase 8; PARP; Plasmodium
Pathway	Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; MAPK/ERK Pathway
Manufacturers Product type	Natural Products

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 mg

available

Request delivery time